Pharmaceutical News, Pharma, Biotech News & Medical Diagnostics at WSJ.com

World » More

World » More

Loading…
Asia » More

Asia » More

Loading…
Hong Kong » More

Hong Kong » More

Loading…
China » More

China » More

Loading…
India » More

India » More

Loading…
Japan » More

Japan » More

Loading…
SE Asia » More

SE Asia » More

Loading…
Business » More

Business » More

Loading…
Markets » More

Markets » More

Loading…
Tech » More

Tech » More

Loading…
Life & Style » More

Life & Style » More

Loading…
Real Estate » More

Real Estate » More

Loading…
Jobs » More

Jobs » More

Loading…
Opinion » More

Opinion » More

Loading…

Breaking News

A Chinese court said Apple has agreed to pay $60 million to settle a trademark dispute over the iPad name.

Subscriber Content Read Preview

Amylin's High-Price Cure for Big Pharma
Bristol-Myers Squibb and AstraZeneca are joining forces to buy U.S. biotech group Amylin for a total of $7 billion. While Amylin's injectable hormone treatments for type two diabetes are a hot property to drug companies with falling sales, a 95% premium to its prebid share price still looks a sting for BMS and AstraZeneca investors.
Subscriber Content Read Preview

Bristol's Amylin Deal Expands Diabetes Roster
Bristol-Myers Squibb's agreement to acquire diabetes-drug maker Amylin Pharmaceuticals for $5.3 billion gives Bristol more heft in a fast-growing market, but the New York-based pharmaceutical company still faces larger rivals with dominant products.
Health-Law Battle Enters Next Round
A new front opened in efforts to reshape how the government implements Obama's health-care overhaul. Employers, insurers, hospitals, drug makers and others are angling for an advantage.
- Video: Battle Begins to Reshape Law
Subscriber Content Read Preview

Glaxo Extends U.S. Biotech Bid
GlaxoSmithKline kept up the pressure on Human Genome Sciences by extending its offer for the U.S. biotech company to July 20, four days after the target company's deadline for finding alternative suitors.
When Will Computers Do What the Brain Does?
Ray Kurzweil discussed advances in artificial intelligence and nanotechnology, and what it will mean to be human after the year 2029.
- Video: The Merging of Computers and Humans
- Video: The Similarities of Humans and Machines
Subscriber Content Read Preview

No Hitches For Nasdaq On Latest Offerings
Ruling Underscores Hospitals' Strategy
Subscriber Content Read Preview

Supremes Get Mixed Review From Health-Care Investors
What the Ruling Means for Consumers
Subscriber Content Read Preview

Survey: Business Owners Struggle With Health-Care Law
More

Latest Pharmaceuticals & Biotech Headlines

FromDow Jones Newswires

More Industries

Subscriber Content

View an interactive map that shows you how stocks in the Pharmaceuticals & Biotech sector are doing today, at a glance.

Get in-depth research on Pharmaceuticals & Biotech companies, including complete news and financials, earnings estimates and more.

Job Opportunities POST A JOB

MORE JOBS AND CAREER NEWS

FINS for Employers & Recruiters »POST A JOB

Ask a question about anything you choose, and let readers from the Journal Community answer it.

Notify me when I receive answers

*Required

Journal Community

close window

Hello

Your question to the Journal Community Your comments on articles will show your real name and not a username.Why?

Create a Journal Community profile to avoid this message in the future. (As a member you agree to use your real name when participating in the Journal Community)